Ludwig J, Hoffle-Maas A, Samochocki M, Luttmann E, Albuquerque EX, Fels G, Maelicke A (2010) <br />Localization by site-directed mutagenesis of a galantamine binding site on alpha7 nicotinic acetylcholine receptor extracellular domain<br /><i>J Recept Signal Transduct Res</i> <b>30</b>: 469<br /><br />Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK (2010) <br />Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy<br /><i>Journal of Molecular Neuroscience</i> <b>40</b>: 135<br /><br />Albuquerque EX, Pereira EF, Samochocki M, Alkondon M, Christoph U, Maelicke A (2004) <br />Nicotinic receptor modulation.<br /><i>Cholinergic Mechanisms, CRC Press</i> <br /><br />Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A (2003) <br />Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors<br /><i>Journal of Pharmacology & Experimental Therapeutics</i> <b>305</b>: 1024<br /><br />Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M (2001) <br />Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease<br /><i>Biological Psychiatry</i> <b>49</b>: 279<br /><br />Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX (2000) <br />Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease<br /><i>Behavioural Brain Research</i> <b>113</b>: 199<br /><br />Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A (2000) <br />Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR<br /><i>Acta Neurologica Scandinavica Supplementum</i> <b>176</b>: 68<br /><br />